查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2128005

骨癌治療市場規模、佔有率、成長、全球產業分析、區域趨勢及2026年至2034年預測。

Bone Cancer Treatment Market Size, Share, Growth and Global Industry Analysis, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 190 Pages | 商品交期: 2-3個工作天內

價格

骨癌治療市場的成長要素

全球骨癌治療市場預計到2025年將達到13.1億美元，並從2026年的14億美元成長到2034年的23.8億美元，預測期內複合年成長率（CAGR）為6.82%。北美將引領全球市場，到2025年將佔據45.8%的市場佔有率，這得益於其先進的腫瘤治療基礎設施、高額的醫療保健支出以及創新癌症主導的快速普及。

骨癌治療不僅包括原發性骨癌（如骨癌、伊文氏肉瘤、軟骨肉瘤和脊索瘤）的治療，還包括轉移性骨病變和骨骼相關併發症的治療。隨著標靶治療、免疫療法、抗體藥物複合體和孤兒藥研究的進展，骨癌治療格局正在發生巨大變化。製藥公司持續投入大量資金進行臨床試驗，旨在提高罕見和進行性骨癌患者的存活率，並滿足他們尚未滿足的醫療需求。

骨癌治療市場趨勢

影響骨癌治療市場的最重要趨勢之一是多學科綜合治療策略的日益普及。醫院和癌症中心擴大將化療、手術、放射線治療、標靶治療和支持性護理相結合，以改善治療效果。這種綜合治療方法有助於降低復發率、保護肢體功能並提高進行性骨癌患者的整體存活率。

研究合作也不斷增加。 2025年9月，突破癌症基金會投資1500萬美元成立了“對抗骨肉瘤團隊實驗室”，這表明業界對進行性骨癌研究和創新聯合治療的興趣日益濃厚。

市場促進因素

骨癌和骨轉移的發生率不斷上升，持續推動市場擴張。骨癌、伊文氏肉瘤和轉移性骨癌的診斷數量不斷增加，導致對化療藥物、分子標靶療法、疼痛管理方案和輔助治療產品的需求持續成長。

持續的產品研發進一步推動了市場成長。 2025年1月，OS Therapies公司宣布了OST-HER2治療復發骨癌患者的IIb期臨床試驗的正面結果。該試驗表明，患者的無事件生存期有所改善，並為未來的商業化提供了支持。

市場限制因素

儘管市場呈現穩定成長態勢，但仍有諸多挑戰阻礙其擴張。骨癌治療後常復發或轉移，導致長期存活率降低。目前以化療為主的治療方法對晚期癌症療效有限，且常伴隨嚴重的副作用。

臨床研究不斷揭示現有治療方案的局限性。 2025年發表的一項研究表明，強化常規化療並未顯著提高高風險骨癌患者的無疾病存活期，凸顯了開發更有效治療方法的緊迫性。

市場機遇

針對罕見癌症和孤兒藥的研發項目正在全球市場創造巨大的機會。監管激勵措施、加速核准流程、市場獨佔權和財政支持正在加速製藥公司開發骨癌、軟骨肉瘤、脊索瘤和伊文氏肉瘤的創新療法。

2025年7月，Lithea Pharma公司憑藉其創新療法LIT1001獲得美國FDA授予的孤兒藥資格認定。該療法旨在將化療藥物直接輸送到骨癌腫瘤。這凸顯了精準腫瘤學領域日益成長的投入。

市場挑戰

開發針對復發性和轉移性骨癌的有效療法仍面臨挑戰。儘管人們對化療的毒性和存活期改善有限感到擔憂，但標準化療仍然是主要的治療。由於骨癌的罕見性，需要進行長期的臨床試驗，因此標靶治療和免疫療法的臨床開發受到高昂的研發成本和監管障礙的限制。

市場區隔

按藥物類別分類，細胞毒性化學療法藥物由於其在骨癌和伊文氏肉瘤標準治療方案中的廣泛應用，預計在2025年將佔據市場主導地位。 IDH抑制劑細分市場預計將在整個預測期內保持最快的成長速度。

按癌症類型分類，骨癌由於發病率高且需要強化治療，因此佔據了最大的市場佔有率。 「其他骨癌」類別預計到2034年將維持穩定成長。

按年齡層別分類，由於治療費用高昂以及先進療法的日益普及，成人佔銷售額的最大佔有率，但兒童市場也在穩步擴張。

就治療方法而言，化療仍保持市場主導地位，因為它仍然是術前和術後治療的基礎。然而，隨著臨床研究的進展，免疫療法預計將迎來更快的成長。

在給藥途徑方面，由於醫院廣泛使用靜脈注射抗癌藥物，因此腸外給藥成為​​主要方法。

醫院藥房繼續保持其作為主要分銷管道的地位，這得益於專業的癌症護理、靜脈輸液服務和冷鏈藥物管理。

區域展望

北美仍然是最大的區域市場，預計到2025年將達到6億美元，這得益於強大的癌症研究計畫、早期參與臨床試驗的機會以及創新療法的快速推廣。美國憑藉其先進的醫療基礎設施和對罕見癌症治療不斷成長的投資，持續推動區域需求。

由於專門的肉瘤治療中心和臨床指南的改進，歐洲預計到 2026 年將達到 3.8 億美元。

預計到 2026 年，亞太地區的癌症治療市場規模將達到 2.8 億美元，這得益於中國、日本和印度癌症治療基礎設施的擴張、診斷技術的改進以及先進癌症治療的普及。

在拉丁美洲、中東和非洲，隨著人們對癌症的認知、診斷率和獲得專業癌症治療的機會不斷提高，預計癌症發病率將保持溫和成長。

目錄

第1章：引言

第2章執行摘要

第3章 市場動態

  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢
  • 市場挑戰

第4章：主要考慮因素

  • 各國/地區骨癌盛行率（2025 年）
  • 新產品發布：按主要公司分類
  • 主要地區和國家的監管情況概述
  • 主要產業趨勢（合併、收購、合作等）
  • 新產品發布：按主要公司分類
  • 管道分析：按主要公司分類

第5章：2021-2034年全球骨癌治療市場分析、洞察與預測

  • 市場分析、洞察與預測：按藥物類別分類
    • 細胞毒性化學療法藥物
    • 蛋白酪氨酸激酶抑制劑（TKIs）
    • 免疫查核點抑制劑
    • RANKL抑制劑
    • IDH抑制劑
    • 雙磷酸鹽類藥物
    • 其他
  • 市場分析、洞察與預測：按癌症類型分類
    • 骨癌
    • 伊文氏肉瘤
    • 軟骨肉瘤
    • 脊索瘤
    • 其他
  • 市場分析、洞察與預測：按年齡層別分類
    • 兒童
    • 成人
  • 市場分析、洞察與預測：按治療方式分類
    • 化療
    • 標靶治療
    • 免疫療法
    • 其他
  • 市場分析、洞察與預測：按給藥途徑
    • 口服
    • 腸外
  • 市場分析、洞察與預測：按分銷管道分類
    • 醫院藥房
    • 專科藥房
    • 藥局和零售藥房
    • 網路藥房
  • 分析、洞察與預測：按地區分類
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第6章：北美骨癌治療市場分析、洞察與預測（2021-2034年）

  • 國家
    • 美國
    • 加拿大

第7章：歐洲骨癌治療市場分析、洞察與預測（2021-2034年）

  • 國家
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 斯堪地那維亞
    • 其他歐洲國家

第8章：亞太地區骨癌治療市場分析、洞察與預測（2021-2034年）

  • 國家
    • 中國
    • 日本
    • 印度
    • 東南亞
    • 澳洲
    • 其他亞太國家

第9章：拉丁美洲骨癌治療市場分析、洞察與預測（2021-2034年）

  • 國家
    • 巴西
    • 墨西哥
    • 其他拉丁美洲國家

第10章：中東和非洲骨癌治療市場分析、洞察與預測（2021-2034年）

  • 國家
    • GCC
    • 南非
    • 其他中東和非洲國家

第11章 競爭分析

  • 全球市佔率分析（2025 年）
  • 公司簡介
    • Amgen Inc.
    • Novartis AG
    • Pfizer Inc.
    • Fresenius Kabi AG
    • Hikma Pharmaceuticals PLC
    • Teva Pharmaceutical Industries Ltd.
    • Accord Healthcare Ltd.
    • Baxter International Inc.
    • Viatris Inc.
    • GSK plc.
Product Code: FBI117390

Growth Factors of bone cancer treatment Market

The global bone cancer treatment market was valued at USD 1.31 billion in 2025 and is expected to grow from USD 1.40 billion in 2026 to USD 2.38 billion by 2034, registering a CAGR of 6.82% during the forecast period. North America dominated the global market with a 45.8% market share in 2025, supported by advanced oncology infrastructure, higher healthcare spending, and rapid adoption of innovative cancer therapies.

Bone cancer treatment includes therapies for primary bone cancers such as osteosarcoma, Ewing sarcoma, chondrosarcoma, and chordoma, along with treatments for metastatic bone disease and bone-related complications. Growing research into targeted therapies, immunotherapies, antibody-drug conjugates, and orphan drugs is transforming the treatment landscape. Pharmaceutical companies continue investing heavily in clinical trials to improve survival rates and address the unmet medical needs of patients suffering from rare and aggressive bone cancers.

Bone Cancer Treatment Market Trends

One of the most significant trends shaping the bone cancer treatment market is the growing adoption of multimodal treatment strategies. Hospitals and cancer centers are increasingly combining chemotherapy, surgery, radiation therapy, targeted therapies, and supportive care to improve treatment outcomes. This integrated approach helps reduce recurrence, preserve limb function, and improve overall survival in patients with aggressive bone cancers.

Research collaborations are also increasing. In September 2025, Break Through Cancer invested USD 15 million to establish the Defying Osteosarcoma TeamLab, highlighting the industry's growing focus on advanced osteosarcoma research and innovative combination therapies.

Market Drivers

The rising prevalence of bone cancer and bone metastases continues to drive market expansion. Increasing diagnoses of osteosarcoma, Ewing sarcoma, and metastatic bone cancers have created sustained demand for chemotherapy drugs, targeted therapies, pain management solutions, and supportive care products.

Continuous product development further strengthens market growth. In January 2025, OS Therapies reported positive Phase 2b results for OST-HER2 in recurrent osteosarcoma patients, demonstrating improved event-free survival and supporting future commercialization opportunities.

Market Restraints

Despite steady growth, several challenges limit market expansion. Bone cancers often recur or metastasize after treatment, reducing long-term survival rates. Current chemotherapy-based regimens frequently produce severe side effects while offering limited improvements in advanced-stage disease.

Clinical studies continue to demonstrate the limitations of existing treatment protocols. Findings published during 2025 showed that intensifying conventional chemotherapy failed to significantly improve disease-free survival among high-risk osteosarcoma patients, emphasizing the urgent need for more effective therapies.

Market Opportunities

Rare cancer and orphan drug development programs are creating significant opportunities across the global market. Regulatory incentives, accelerated approval pathways, market exclusivity, and financial support encourage pharmaceutical companies to develop innovative therapies for osteosarcoma, chondrosarcoma, chordoma, and Ewing sarcoma.

In July 2025, Lithea Pharma received Orphan Drug Designation from the U.S. FDA for LIT1001, a novel therapy designed to deliver chemotherapy directly to osteosarcoma tumors, highlighting the growing investment in precision oncology.

Market Challenges

Developing effective therapies for recurrent and metastatic bone cancers remains difficult. Standard chemotherapy remains the primary treatment despite toxicity concerns and limited survival improvements. Clinical development for targeted therapies and immunotherapies requires lengthy trials due to the rarity of bone cancers, creating high development costs and regulatory hurdles for manufacturers.

Market Segmentation

Based on drug class, cytotoxic chemotherapy agents dominated the market in 2025 due to their widespread use in standard treatment regimens for osteosarcoma and Ewing sarcoma. The IDH inhibitors segment is expected to register the fastest growth throughout the forecast period.

By cancer type, osteosarcoma accounted for the largest market share owing to its higher incidence and intensive treatment requirements. The other bone cancers category is projected to witness healthy growth through 2034.

Based on age group, adults represented the largest revenue share due to higher treatment spending and greater use of advanced therapies, while the pediatric segment continues expanding steadily.

By therapy, chemotherapy maintained market dominance because it remains the foundation of treatment before and after surgery. However, immunotherapy is anticipated to experience faster growth as clinical research advances.

Based on route of administration, parenteral therapies dominated owing to the widespread use of intravenous oncology drugs administered in hospitals.

Hospital pharmacies remained the leading distribution channel, supported by specialized oncology care, infusion services, and cold-chain drug management.

Regional Outlook

North America remained the largest regional market, reaching USD 0.60 billion in 2025, supported by strong cancer research programs, early clinical trial access, and rapid adoption of innovative therapies. The U.S. continues to lead regional demand due to advanced healthcare infrastructure and increasing investment in rare cancer treatment.

Europe is expected to reach USD 0.38 billion in 2026, driven by specialized sarcoma treatment centers and improved clinical guidelines.

Asia Pacific is projected to reach USD 0.28 billion in 2026, supported by expanding cancer care infrastructure, improved diagnosis, and increasing access to advanced oncology treatments across China, Japan, and India.

Latin America and the Middle East & Africa are expected to witness moderate growth as awareness, diagnosis rates, and access to specialized cancer treatment continue improving.

Competitive Landscape

The bone cancer treatment market remains moderately fragmented, with leading pharmaceutical companies strengthening their portfolios through research, regulatory approvals, acquisitions, and pipeline expansion. Major companies include Amgen Inc., Novartis AG, Pfizer Inc., Fresenius Kabi AG, Hikma Pharmaceuticals PLC, Teva Pharmaceutical Industries Ltd., Accord Healthcare Ltd., Baxter International Inc., Viatris Inc., and GSK plc.

Recent industry developments include Iterion Therapeutics initiating a Phase 2 clinical trial for tegavivint in February 2026, Telix Pharmaceuticals beginning Phase 1 evaluation of TLX090 in October 2025, and OS Therapies expanding its oncology portfolio through the acquisition of Advaxis immunotherapy assets in April 2025.

Conclusion

The global bone cancer treatment market is expected to experience steady growth through 2034 as pharmaceutical companies continue investing in targeted therapies, immunotherapies, antibody-drug conjugates, and orphan drug programs for rare bone cancers. Although recurrence rates, limited treatment options, and lengthy clinical development remain significant challenges, ongoing innovation, supportive regulatory initiatives, and expanding research collaborations are expected to improve patient outcomes and create long-term growth opportunities across the global bone cancer treatment market.

Segmentation By Drug Class, Cancer Type, Age Group, Therapy, Route of Administration, Distribution Channel, and Region

By Drug Class * Cytotoxic Chemotherapy Agents

  • Tyrosine Kinase Inhibitors (TKIs)
  • Immune Checkpoint Inhibitors
  • RANKL Inhibitors
  • IDH Inhibitors
  • Bisphosphonates
  • Others

By Cancer Type * Osteosarcoma

  • Ewing Sarcoma
  • Chondrosarcoma
  • Chordoma
  • Others

By Age Group * Pediatric

  • Adults

By Therapy * Chemotherapy

  • Targeted Therapy
  • Immunotherapy
  • Others

By Route of Administration * Oral

  • Parenteral

By Distribution Channel * Hospital Pharmacies

  • Specialty Pharmacies
  • Drug Stores & Retail Pharmacies
  • Online Pharmacies

By Region * North America (By Drug Class, Cancer Type, Age Group, Therapy, Route of Administration, Distribution Channel, and Country)

    • U.S.
    • Canada
  • Europe (By Drug Class, Cancer Type, Age Group, Therapy, Route of Administration, Distribution Channel, and Country/Sub-region)
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Drug Class, Cancer Type, Age Group, Therapy, Route of Administration, Distribution Channel, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Drug Class, Cancer Type, Age Group, Therapy, Route of Administration, Distribution Channel, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Drug Class, Cancer Type, Age Group, Therapy, Route of Administration, Distribution Channel, and Country/Sub-region)
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends
  • 3.5. Market Challenges

4. Key Insights

  • 4.1. Prevalence of Bone Cancer, By Countries/Region, 2025
  • 4.2. New Product Launches, By Key Players
  • 4.3. Overview of Regulatory Scenario, By Key Regions/ Countries
  • 4.4. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
  • 4.5. New Product Launches, By Key Players
  • 4.6. Pipeline Analysis, By Key Players

5. Global Bone Cancer Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Drug Class
    • 5.1.1. Cytotoxic Chemotherapy Agents
    • 5.1.2. Tyrosine Kinase Inhibitors (TKIs)
    • 5.1.3. Immune Checkpoint Inhibitors
    • 5.1.4. RANKL Inhibitors
    • 5.1.5. IDH Inhibitors
    • 5.1.6. Bisphosphonates
    • 5.1.7. Others
  • 5.2. Market Analysis, Insights and Forecast - By Cancer Type
    • 5.2.1. Osteosarcoma
    • 5.2.2. Ewing Sarcoma
    • 5.2.3. Chondrosarcoma
    • 5.2.4. Chordoma
    • 5.2.5. Others
  • 5.3. Market Analysis, Insights and Forecast - By Age Group
    • 5.3.1. Pediatric
    • 5.3.2. Adults
  • 5.4. Market Analysis, Insights and Forecast - By Therapy
    • 5.4.1. Chemotherapy
    • 5.4.2. Targeted Therapy
    • 5.4.3. Immunotherapy
    • 5.4.4. Others
  • 5.5. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.5.1. Oral
    • 5.5.2. Parenteral
  • 5.6. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.6.1. Hospital Pharmacies
    • 5.6.2. Specialty Pharmacies
    • 5.6.3. Drug Stores & Retail Pharmacies
    • 5.6.4. Online Pharmacies
  • 5.7. Market Analysis, Insights and Forecast - Region
    • 5.7.1. North America
    • 5.7.2. Europe
    • 5.7.3. Asia Pacific
    • 5.7.4. Latin America
    • 5.7.5. Middle East & Africa

6. North America Bone Cancer Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Drug Class
    • 6.1.1. Cytotoxic Chemotherapy Agents
    • 6.1.2. Tyrosine Kinase Inhibitors (TKIs)
    • 6.1.3. Immune Checkpoint Inhibitors
    • 6.1.4. RANKL Inhibitors
    • 6.1.5. IDH Inhibitors
    • 6.1.6. Bisphosphonates
    • 6.1.7. Others
  • 6.2. Market Analysis, Insights and Forecast - By Cancer Type
    • 6.2.1. Osteosarcoma
    • 6.2.2. Ewing Sarcoma
    • 6.2.3. Chondrosarcoma
    • 6.2.4. Chordoma
    • 6.2.5. Others
  • 6.3. Market Analysis, Insights and Forecast - By Age Group
    • 6.3.1. Pediatric
    • 6.3.2. Adults
  • 6.4. Market Analysis, Insights and Forecast - By Therapy
    • 6.4.1. Chemotherapy
    • 6.4.2. Targeted Therapy
    • 6.4.3. Immunotherapy
    • 6.4.4. Others
  • 6.5. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.5.1. Oral
    • 6.5.2. Parenteral
  • 6.6. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.6.1. Hospital Pharmacies
    • 6.6.2. Specialty Pharmacies
    • 6.6.3. Drug Stores & Retail Pharmacies
    • 6.6.4. Online Pharmacies
  • 6.7. Market Analysis, Insights and Forecast - By Country
    • 6.7.1. U.S.
    • 6.7.2. Canada

7. Europe Bone Cancer Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Drug Class
    • 7.1.1. Cytotoxic Chemotherapy Agents
    • 7.1.2. Tyrosine Kinase Inhibitors (TKIs)
    • 7.1.3. Immune Checkpoint Inhibitors
    • 7.1.4. RANKL Inhibitors
    • 7.1.5. IDH Inhibitors
    • 7.1.6. Bisphosphonates
    • 7.1.7. Others
  • 7.2. Market Analysis, Insights and Forecast - By Cancer Type
    • 7.2.1. Osteosarcoma
    • 7.2.2. Ewing Sarcoma
    • 7.2.3. Chondrosarcoma
    • 7.2.4. Chordoma
    • 7.2.5. Others
  • 7.3. Market Analysis, Insights and Forecast - By Age Group
    • 7.3.1. Pediatric
    • 7.3.2. Adults
  • 7.4. Market Analysis, Insights and Forecast - By Therapy
    • 7.4.1. Chemotherapy
    • 7.4.2. Targeted Therapy
    • 7.4.3. Immunotherapy
    • 7.4.4. Others
  • 7.5. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.5.1. Oral
    • 7.5.2. Parenteral
  • 7.6. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.6.1. Hospital Pharmacies
    • 7.6.2. Specialty Pharmacies
    • 7.6.3. Drug Stores & Retail Pharmacies
    • 7.6.4. Online Pharmacies
  • 7.7. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.7.1. U.K.
    • 7.7.2. Germany
    • 7.7.3. France
    • 7.7.4. Italy
    • 7.7.5. Spain
    • 7.7.6. Scandinavia
    • 7.7.7. Rest of Europe

8. Asia Pacific Bone Cancer Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Drug Class
    • 8.1.1. Cytotoxic Chemotherapy Agents
    • 8.1.2. Tyrosine Kinase Inhibitors (TKIs)
    • 8.1.3. Immune Checkpoint Inhibitors
    • 8.1.4. RANKL Inhibitors
    • 8.1.5. IDH Inhibitors
    • 8.1.6. Bisphosphonates
    • 8.1.7. Others
  • 8.2. Market Analysis, Insights and Forecast - By Cancer Type
    • 8.2.1. Osteosarcoma
    • 8.2.2. Ewing Sarcoma
    • 8.2.3. Chondrosarcoma
    • 8.2.4. Chordoma
    • 8.2.5. Others
  • 8.3. Market Analysis, Insights and Forecast - By Age Group
    • 8.3.1. Pediatric
    • 8.3.2. Adults
  • 8.4. Market Analysis, Insights and Forecast - By Therapy
    • 8.4.1. Chemotherapy
    • 8.4.2. Targeted Therapy
    • 8.4.3. Immunotherapy
    • 8.4.4. Others
  • 8.5. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.5.1. Oral
    • 8.5.2. Parenteral
  • 8.6. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.6.1. Hospital Pharmacies
    • 8.6.2. Specialty Pharmacies
    • 8.6.3. Drug Stores & Retail Pharmacies
    • 8.6.4. Online Pharmacies
  • 8.7. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.7.1. China
    • 8.7.2. Japan
    • 8.7.3. India
    • 8.7.4. Southeast Asia
    • 8.7.5. Australia
    • 8.7.6. Rest of Asia Pacific

9. Latin America Bone Cancer Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Drug Class
    • 9.1.1. Cytotoxic Chemotherapy Agents
    • 9.1.2. Tyrosine Kinase Inhibitors (TKIs)
    • 9.1.3. Immune Checkpoint Inhibitors
    • 9.1.4. RANKL Inhibitors
    • 9.1.5. IDH Inhibitors
    • 9.1.6. Bisphosphonates
    • 9.1.7. Others
  • 9.2. Market Analysis, Insights and Forecast - By Cancer Type
    • 9.2.1. Osteosarcoma
    • 9.2.2. Ewing Sarcoma
    • 9.2.3. Chondrosarcoma
    • 9.2.4. Chordoma
    • 9.2.5. Others
  • 9.3. Market Analysis, Insights and Forecast - By Age Group
    • 9.3.1. Pediatric
    • 9.3.2. Adults
  • 9.4. Market Analysis, Insights and Forecast - By Therapy
    • 9.4.1. Chemotherapy
    • 9.4.2. Targeted Therapy
    • 9.4.3. Immunotherapy
    • 9.4.4. Others
  • 9.5. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.5.1. Oral
    • 9.5.2. Parenteral
  • 9.6. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.6.1. Hospital Pharmacies
    • 9.6.2. Specialty Pharmacies
    • 9.6.3. Drug Stores & Retail Pharmacies
    • 9.6.4. Online Pharmacies
  • 9.7. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.7.1. Brazil
    • 9.7.2. Mexico
    • 9.7.3. Rest of Latin America

10. Middle East & Africa Bone Cancer Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Drug Class
    • 10.1.1. Cytotoxic Chemotherapy Agents
    • 10.1.2. Tyrosine Kinase Inhibitors (TKIs)
    • 10.1.3. Immune Checkpoint Inhibitors
    • 10.1.4. RANKL Inhibitors
    • 10.1.5. IDH Inhibitors
    • 10.1.6. Bisphosphonates
    • 10.1.7. Others
  • 10.2. Market Analysis, Insights and Forecast - By Cancer Type
    • 10.2.1. Osteosarcoma
    • 10.2.2. Ewing Sarcoma
    • 10.2.3. Chondrosarcoma
    • 10.2.4. Chordoma
    • 10.2.5. Others
  • 10.3. Market Analysis, Insights and Forecast - By Age Group
    • 10.3.1. Pediatric
    • 10.3.2. Adults
  • 10.4. Market Analysis, Insights and Forecast - By Therapy
    • 10.4.1. Chemotherapy
    • 10.4.2. Targeted Therapy
    • 10.4.3. Immunotherapy
    • 10.4.4. Others
  • 10.5. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.5.1. Oral
    • 10.5.2. Parenteral
  • 10.6. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.6.1. Hospital Pharmacies
    • 10.6.2. Specialty Pharmacies
    • 10.6.3. Drug Stores & Retail Pharmacies
    • 10.6.4. Online Pharmacies
  • 10.7. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.7.1. GCC
    • 10.7.2. South Africa
    • 10.7.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. Amgen Inc.
    • 11.2.2. Novartis AG
    • 11.2.3. Pfizer Inc.
    • 11.2.4. Fresenius Kabi AG
    • 11.2.5. Hikma Pharmaceuticals PLC
    • 11.2.6. Teva Pharmaceutical Industries Ltd.
    • 11.2.7. Accord Healthcare Ltd.
    • 11.2.8. Baxter International Inc.
    • 11.2.9. Viatris Inc.
    • 11.2.10. GSK plc.

List of Tables

  • Table 1: Global Bone Cancer Treatment Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 2: Global Bone Cancer Treatment Market Revenue (USD billion) Forecast, by Cancer Type, 2021-2034
  • Table 3: Global Bone Cancer Treatment Market Revenue (USD billion) Forecast, by Age Group 2021-2034
  • Table 4: Global Bone Cancer Treatment Market Revenue (USD billion) Forecast, by Therapy, 2021-2034
  • Table 5: Global Bone Cancer Treatment Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 6: Global Bone Cancer Treatment Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 7: Global Bone Cancer Treatment Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 8: North America Bone Cancer Treatment Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 9: North America Bone Cancer Treatment Market Revenue (USD billion) Forecast, by Cancer Type, 2021-2034
  • Table 10: North America Bone Cancer Treatment Market Revenue (USD billion) Forecast, by Age Group 2021-2034
  • Table 11: North America Bone Cancer Treatment Market Revenue (USD billion) Forecast, by Therapy, 2021-2034
  • Table 12: North America Bone Cancer Treatment Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 13: North America Bone Cancer Treatment Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 14: North America Bone Cancer Treatment Market Revenue (USD billion) Forecast, by Country, 2021-2034
  • Table 15: Europe Bone Cancer Treatment Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 16: Europe Bone Cancer Treatment Market Revenue (USD billion) Forecast, by Cancer Type, 2021-2034
  • Table 17: Europe Bone Cancer Treatment Market Revenue (USD billion) Forecast, by Age Group 2021-2034
  • Table 18: Europe Bone Cancer Treatment Market Revenue (USD billion) Forecast, by Therapy, 2021-2034
  • Table 19: Europe Bone Cancer Treatment Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 20: Europe Bone Cancer Treatment Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 21: Europe Bone Cancer Treatment Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034
  • Table 22: Asia Pacific Bone Cancer Treatment Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 23: Asia Pacific Bone Cancer Treatment Market Revenue (USD billion) Forecast, by Cancer Type, 2021-2034
  • Table 24: Asia Pacific Bone Cancer Treatment Market Revenue (USD billion) Forecast, by Age Group 2021-2034
  • Table 25: Asia Pacific Bone Cancer Treatment Market Revenue (USD billion) Forecast, by Therapy, 2021-2034
  • Table 26: Asia Pacific Bone Cancer Treatment Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 27: Asia Pacific Bone Cancer Treatment Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 28: Asia Pacific Bone Cancer Treatment Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034
  • Table 29: Latin America Bone Cancer Treatment Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 30: Latin America Bone Cancer Treatment Market Revenue (USD billion) Forecast, by Cancer Type, 2021-2034
  • Table 31: Latin America Bone Cancer Treatment Market Revenue (USD billion) Forecast, by Age Group 2021-2034
  • Table 32: Latin America Bone Cancer Treatment Market Revenue (USD billion) Forecast, by Therapy, 2021-2034
  • Table 33: Latin America Bone Cancer Treatment Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 34: Latin America Bone Cancer Treatment Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 35: Latin America Bone Cancer Treatment Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034
  • Table 36: Middle East & Africa Bone Cancer Treatment Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 37: Middle East & Africa Bone Cancer Treatment Market Revenue (USD billion) Forecast, by Cancer Type, 2021-2034
  • Table 38: Middle East & Africa Bone Cancer Treatment Market Revenue (USD billion) Forecast, by Age Group 2021-2034
  • Table 39: Middle East & Africa Bone Cancer Treatment Market Revenue (USD billion) Forecast, by Therapy, 2021-2034
  • Table 40: Middle East & Africa Bone Cancer Treatment Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 41: Middle East & Africa Bone Cancer Treatment Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 42: Middle East & Africa Bone Cancer Treatment Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Bone Cancer Treatment Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Bone Cancer Treatment Market Value Share (%), by Drug Class, 2025 & 2034
  • Figure 3: Global Bone Cancer Treatment Market Value Share (%), by Cancer Type, 2025 & 2034
  • Figure 4: Global Bone Cancer Treatment Market Value Share (%), by Age Group, 2025 & 2034
  • Figure 5: Global Bone Cancer Treatment Market Value Share (%), by Therapy, 2025 & 2034
  • Figure 6: Global Bone Cancer Treatment Market Value Share (%), by Route of Administration, 2025 & 2034
  • Figure 7: Global Bone Cancer Treatment Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 8: Global Bone Cancer Treatment Market Value Share (%), by Region, 2025 & 2034
  • Figure 9: North America Bone Cancer Treatment Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 10: North America Bone Cancer Treatment Market Value Share (%), by Drug Class, 2025
  • Figure 11: North America Bone Cancer Treatment Market Value (USD billion), by Cancer Type, 2025 & 2034
  • Figure 12: North America Bone Cancer Treatment Market Value Share (%), by Cancer Type, 2025
  • Figure 13: North America Bone Cancer Treatment Market Value (USD billion), by Age Group 2025 & 2034
  • Figure 14: North America Bone Cancer Treatment Market Value Share (%), by Age Group 2025
  • Figure 15: North America Bone Cancer Treatment Market Value (USD billion), by Therapy, 2025 & 2034
  • Figure 16: North America Bone Cancer Treatment Market Value Share (%), by Therapy, 2025
  • Figure 17: North America Bone Cancer Treatment Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 18: North America Bone Cancer Treatment Market Value Share (%), by Route of Administration, 2025
  • Figure 19: North America Bone Cancer Treatment Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 20: North America Bone Cancer Treatment Market Value Share (%), by Distribution Channel, 2025
  • Figure 21: North America Bone Cancer Treatment Market Value (USD billion), by Country, 2025 & 2034
  • Figure 22: North America Bone Cancer Treatment Market Value Share (%), by Country, 2025
  • Figure 23: Europe Bone Cancer Treatment Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 24: Europe Bone Cancer Treatment Market Value Share (%), by Drug Class, 2025
  • Figure 25: Europe Bone Cancer Treatment Market Value (USD billion), by Cancer Type, 2025 & 2034
  • Figure 26: Europe Bone Cancer Treatment Market Value Share (%), by Cancer Type, 2025
  • Figure 27: Europe Bone Cancer Treatment Market Value (USD billion), by Age Group 2025 & 2034
  • Figure 28: Europe Bone Cancer Treatment Market Value Share (%), by Age Group 2025
  • Figure 29: Europe Bone Cancer Treatment Market Value (USD billion), by Therapy, 2025 & 2034
  • Figure 30: Europe Bone Cancer Treatment Market Value Share (%), by Therapy, 2025
  • Figure 31: Europe Bone Cancer Treatment Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 32: Europe Bone Cancer Treatment Market Value Share (%), by Route of Administration, 2025
  • Figure 33: Europe Bone Cancer Treatment Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 34: Europe Bone Cancer Treatment Market Value Share (%), by Distribution Channel, 2025
  • Figure 35: Europe Bone Cancer Treatment Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 36: Europe Bone Cancer Treatment Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 37: Asia Pacific Bone Cancer Treatment Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 38: Asia Pacific Bone Cancer Treatment Market Value Share (%), by Drug Class, 2025
  • Figure 39: Asia Pacific Bone Cancer Treatment Market Value (USD billion), by Cancer Type, 2025 & 2034
  • Figure 40: Asia Pacific Bone Cancer Treatment Market Value Share (%), by Cancer Type, 2025
  • Figure 41: Asia Pacific Bone Cancer Treatment Market Value (USD billion), by Age Group 2025 & 2034
  • Figure 42: Asia Pacific Bone Cancer Treatment Market Value Share (%), by Age Group 2025
  • Figure 43: Asia Pacific Bone Cancer Treatment Market Value (USD billion), by Therapy, 2025 & 2034
  • Figure 44: Asia Pacific Bone Cancer Treatment Market Value Share (%), by Therapy, 2025
  • Figure 45: Asia Pacific Bone Cancer Treatment Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 46: Asia Pacific Bone Cancer Treatment Market Value Share (%), by Route of Administration, 2025
  • Figure 47: Asia Pacific Bone Cancer Treatment Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 48: Asia Pacific Bone Cancer Treatment Market Value Share (%), by Distribution Channel, 2025
  • Figure 49: Asia Pacific Bone Cancer Treatment Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 50: Asia Pacific Bone Cancer Treatment Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 51: Latin America Bone Cancer Treatment Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 52: Latin America Bone Cancer Treatment Market Value Share (%), by Drug Class, 2025
  • Figure 53: Latin America Bone Cancer Treatment Market Value (USD billion), by Cancer Type, 2025 & 2034
  • Figure 54: Latin America Bone Cancer Treatment Market Value Share (%), by Cancer Type, 2025
  • Figure 55: Latin America Bone Cancer Treatment Market Value (USD billion), by Age Group 2025 & 2034
  • Figure 56: Latin America Bone Cancer Treatment Market Value Share (%), by Age Group 2025
  • Figure 57: Latin America Bone Cancer Treatment Market Value (USD billion), by Therapy, 2025 & 2034
  • Figure 58: Latin America Bone Cancer Treatment Market Value Share (%), by Therapy, 2025
  • Figure 59: Latin America Bone Cancer Treatment Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 60: Latin America Bone Cancer Treatment Market Value Share (%), by Route of Administration, 2025
  • Figure 61: Latin America Bone Cancer Treatment Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 62: Latin America Bone Cancer Treatment Market Value Share (%), by Distribution Channel, 2025
  • Figure 63: Latin America Bone Cancer Treatment Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 64: Latin America Bone Cancer Treatment Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 65: Middle East & Africa Bone Cancer Treatment Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 66: Middle East & Africa Bone Cancer Treatment Market Value Share (%), by Drug Class, 2025
  • Figure 67: Middle East & Africa Bone Cancer Treatment Market Value (USD billion), by Cancer Type, 2025 & 2034
  • Figure 68: Middle East & Africa Bone Cancer Treatment Market Value Share (%), by Cancer Type, 2025
  • Figure 69: Middle East & Africa Bone Cancer Treatment Market Value (USD billion), by Age Group 2025 & 2034
  • Figure 70: Middle East & Africa Bone Cancer Treatment Market Value Share (%), by Age Group 2025
  • Figure 71: Middle East & Africa Bone Cancer Treatment Market Value (USD billion), by Therapy, 2025 & 2034
  • Figure 72: Middle East & Africa Bone Cancer Treatment Market Value Share (%), by Therapy, 2025
  • Figure 73: Middle East & Africa Bone Cancer Treatment Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 74: Middle East & Africa Bone Cancer Treatment Market Value Share (%), by Route of Administration, 2025
  • Figure 75: Middle East & Africa Bone Cancer Treatment Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 76: Middle East & Africa Bone Cancer Treatment Market Value Share (%), by Distribution Channel, 2025
  • Figure 77: Middle East & Africa Bone Cancer Treatment Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 78: Middle East & Africa Bone Cancer Treatment Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 79: Global Bone Cancer Treatment Market Share (%), by Company, 2025